GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation

Abstract

Bone metastases occur in patients with advanced-stage prostate cancer (PCa). The cell-cell interaction between PCa and the bone microenvironment forms a vicious cycle that modulates the bone microenvironment, increases bone deformities, and drives tumor growth in the bone. However, the molecular mechanisms of PCa-mediated modulation of the bone microenvironment are complex and remain poorly defined. Here, we evaluated growth differentiation factor-15 (GDF15) function using in vivo preclinical PCa-bone metastasis mouse models and an in vitro bone cell coculture system. Our results suggest that PCa-secreted GDF15 promotes bone metastases and induces bone microarchitectural alterations in a preclinical xenograft model. Mechanistic studies revealed that GDF15 increases osteoblast function and facilitates the growth of PCa in bone by activating osteoclastogenesis through osteoblastic production of CCL2 and RANKL and recruitment of osteomacs. Altogether, our findings demonstrate the critical role of GDF15 in the modulation of the bone microenvironment and subsequent development of PCa bone metastasis.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin., 2019, 69: 7-34

[2] Sartor O, de Bono JS. Metastatic Prostate Cancer. N. Engl. J. Med., 2018, 378: 645-657

[3] Bubendorf L et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol., 2000, 31: 578-583

[4] Norgaard M et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J. Urol., 2010, 184: 162-167

[5] Tsuzuki S, Park SH, Eber MR, Peters CM, Shiozawa Y. Skeletal complications in cancer patients with bone metastases. Int J. Urol., 2016, 23: 825-832

[6] Siddiqui JA, Partridge NC. Physiological bone remodeling: systemic regulation and growth factor involvement. Physiol. (Bethesda), 2016, 31: 233-245

[7] Shupp A. B., Kolb A. D., Mukhopadhyay D., Bussard K. M. Cancer metastases to bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers (Basel) 10, (2018).

[8] Saad F, Eastham JA, Smith MR. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol. Oncol., 2012, 30: 369-378

[9] Fournier PG et al. The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell, 2015, 27: 809-821

[10] Tu WH et al. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia, 2003, 5: 267-277

[11] Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J. Cell Physiol., 2010, 224: 626-635

[12] Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J. Diabetes Res., 2015, 2015: 490842

[13] Vocka M et al. Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer. Cancer Biomark., 2018, 21: 869-874

[14] Wang Y, Jiang T, Jiang M, Gu S. Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis. BMC Cancer, 2019, 19

[15] Karan D et al. Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem. Biophys. Res. Commun., 2003, 305: 598-604

[16] Kaur S et al. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One, 2013, 8: e55171

[17] Windrichova J et al. MIC1/GDF15 as a Bone Metastatic Disease Biomarker. Anticancer Res., 2017, 37: 1501-1505

[18] Emmerson PJ et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat. Med., 2017, 23: 1215-1219

[19] Hsu JY et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature, 2017, 550: 255-259

[20] Mullican SE et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med., 2017, 23: 1150-1157

[21] Yang L et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med., 2017, 23: 1158-1166

[22] Tsai VW et al. The anorectic actions of the TGFbeta cytokine MIC-1/GDF15 require an intact brainstem area postrema and nucleus of the solitary tract. PLoS One, 2014, 9: e100370

[23] Senapati S et al. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene, 2010, 29: 1293-1302

[24] Lo CH, Lynch CC. Multifaceted roles for macrophages in prostate cancer skeletal metastasis. Front. Endocrinol. (Lausanne), 2018, 9: 247

[25] Wu AC et al. CD169(+) macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer. J. Pathol., 2016, 239: 218-230

[26] Mizutani K et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia, 2009, 11: 1235-1242

[27] Mulholland BS, Forwood MR, Morrison NA. Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) drives activation of bone remodelling and skeletal metastasis. Curr. Osteoporos. Rep., 2019, 17: 538-547

[28] Loberg RD et al. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 2007, 9: 556-562

[29] Roca H et al. CCL2 and interleukin-6 promote survival of human CD11b⁺ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem., 2009, 284: 34342-34354

[30] Kyriakides TR et al. The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am. J. Pathol., 2004, 165: 2157-2166

[31] Mimeault M, Johansson SL, Batra SK. Pathobiological implications of the expression of EGFR, pAkt, NF-kappaB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One, 2012, 7: e31919

[32] Mimeault M, Johansson SL, Batra SK. Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1. Br. J. Cancer, 2013, 108: 1079-1091

[33] Wang W et al. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. Oncogene, 2019, 38: 4540-4559

[34] Tassone E et al. KLF4 as a rheostat of osteolysis and osteogenesis in prostate tumors in the bone. Oncogene, 2019, 38: 5766-5777

[35] Brasso K et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate, 2006, 66: 503-513

[36] Dai J et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin. Cancer Res., 2014, 20: 617-630

[37] Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res., 2005, 65: 7554-7560

[38] Morrissey C, Kostenuik PL, Brown LG, Vessella RL, Corey E. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer, 2007, 7

[39] Pfitzenmaier J et al. Characterization of C4-2 prostate cancer bone metastases and their response to castration. J. Bone Min. Res., 2003, 18: 1882-1888

[40] Guise TA. The vicious cycle of bone metastases. J. Musculoskelet. Neuronal Interact., 2002, 2: 570-572

[41] Kiviranta R et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone, 2005, 36: 159-172

[42] Li CY et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J. Bone Min. Res., 2006, 21: 865-875

[43] Siddiqui JA et al. Catabolic effects of human PTH (1-34) on bone: requirement of monocyte chemoattractant protein-1 in murine model of hyperparathyroidism. Sci. Rep., 2017, 7

[44] Siddiqui JA et al. Osteoblastic monocyte chemoattractant protein-1 (MCP-1) mediation of parathyroid hormone’s anabolic actions in bone implicates TGF-beta signaling. Bone, 2021, 143: 115762

[45] Lu Y et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate, 2006, 66: 1311-1318

[46] Siddiqui JA, Partridge NC. CCL2/Monocyte chemoattractant protein 1 and parathyroid hormone action on bone. Front. Endocrinol. (Lausanne), 2017, 8: 49

[47] Winkler IG et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood, 2010, 116: 4815-4828

[48] Chang MK et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J. Immunol., 2008, 181: 1232-1244

[49] Sinder BP, Pettit AR, McCauley LK. Macrophages: Their Emerging Roles in Bone. J. Bone Min. Res., 2015, 30: 2140-2149

[50] Ashley JW et al. Genetic ablation of CD68 results in mice with increased bone and dysfunctional osteoclasts. PLoS One, 2011, 6: e25838

[51] Westhrin M et al. Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. Haematologica, 2015, 100: e511-e514

[52] Wakchoure S et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate, 2009, 69: 652-661

[53] Vanhara P et al. Growth/differentiation factor-15 inhibits differentiation into osteoclasts-a novel factor involved in control of osteoclast differentiation. Differentiation, 2009, 78: 213-222

[54] Nakai Y et al. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res., 2019, 7: 1

[55] Johnen H et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med., 2007, 13: 1333-1340

[56] Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc. Natl. Acad. Sci. USA, 2000, 97: 109-114

[57] Xu J et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ. Res., 2006, 98: 342-350

[58] Ge C, Xiao G, Jiang D, Franceschi RT. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol., 2007, 176: 709-718

[59] Xiao G et al. Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J. Bone Min. Res., 2002, 17: 101-110

[60] Xiao G, Jiang D, Gopalakrishnan R, Franceschi RT. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J. Biol. Chem., 2002, 277: 36181-36187

[61] Xiao G et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem., 2000, 275: 4453-4459

[62] Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J. Cell Sci., 2009, 122: 716-726

[63] Juarez P, Guise TA. TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone, 2011, 48: 23-29

[64] Hu Z et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Hum. Gene Ther., 2012, 23: 871-882

[65] Wan X et al. Effect of transforming growth factor beta (TGF-beta) receptor I kinase inhibitor on prostate cancer bone growth. Bone, 2012, 50: 695-703

[66] Bootcov MR et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. USA, 1997, 94: 11514-11519

[67] Seshacharyulu P et al. FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis. Oncogene, 2019, 38: 5265-5280

[68] Muniyan S et al. Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling. Clin. Cancer Res., 2020, 26: 5720-5734

[69] Mimeault M et al. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. Oncotarget, 2015, 6: 3887-3903

[70] Park SI, Kim SJ, McCauley LK, Gallick GE. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr. Protoc. Pharm. Chapter 14, 2010, 14: 15

[71] Bouxsein ML et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Min. Res., 2010, 25: 1468-1486

[72] Siddiqui JA et al. A naturally occurring rare analog of quercetin promotes peak bone mass achievement and exerts anabolic effect on osteoporotic bone. Osteoporos. Int., 2011, 22: 3013-3027

[73] Pothuraju R et al. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance. Mol. Cancer, 2020, 19

[74] Siddiqui JA et al. 8,8”-Biapigeninyl stimulates osteoblast functions and inhibits osteoclast and adipocyte functions: Osteoprotective action of 8,8”-biapigeninyl in ovariectomized mice. Mol. Cell Endocrinol., 2010, 323: 256-267

[75] Trivedi R et al. Kaempferol has osteogenic effect in ovariectomized adult Sprague-Dawley rats. Mol. Cell Endocrinol., 2008, 289: 85-93

[76] Wang Y et al. BK ablation attenuates osteoblast bone formation via integrin pathway. Cell Death Dis., 2019, 10

[77] Vengoji R et al. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J. Exp. Clin. Cancer Res., 2019, 38: 266

[78] Wang F et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn., 2012, 14: 22-29

Funding

U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)(U01 CA185148)

U.S. Department of Defense (United States Department of Defense)(W81XWH-21-1-0640)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)